April 22 (Reuters) - The ousted director of a key U.S. agency charged with developing drugs to fight the coronavirus pandemic on Wednesday said he was dismissed because he called for careful vetting of a treatment frequently touted by President Donald Trump.
Rick Bright said in a statement that he was replaced as director of the Biomedical Advanced Research and Development Authority, or BARDA, and reassigned to a new role because he resisted efforts to push hydroxychloroquine and the related chloroquine as cures for COVID-19, the respiratory illness caused by the coronavirus.
“While I am prepared to look at all options and to think ‘outside the box’ for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public,” Bright said in the statement, reported by multiple U.S. media outlets on Wednesday.
Bright said the U.S. government has promoted the medicines as a “panacea” even though they “clearly lack scientific merit.”
Bright has retained a law firm, Katz, Marshall & Banks, known for representing whistleblowers.
The U.S. Department of Health and Human Services, which oversees BARDA, said on Tuesday that Bright had been moved to a new public-private partnership under the National Institutes of Health announced last week.
BARDA officials did not immediately respond to a request for comment on Wednesday.
Bright, an expert in vaccines and therapeutics, was named BARDA’s director in 2016 before Trump took office as president.
Trump has repeatedly promoted chloroquine and hydroxychloroquine as potential treatments for COVID-19, including saying early this month, “I may take it,” even though doctors said the drugs’ effectiveness were unproven and further tests were required.
In the absence of any known effective treatments, doctors on the frontlines said they began using hydroxychloroquine and chloroquine on deteriorating patients based on a few small studies suggesting a possible benefit. Some said they had come under pressure from patients to use the therapies widely touted by Trump and other supporters.
After Reuters reported on that pattern, the U.S. Centers for Disease Control and Prevention removed from its website highly unusual guidance informing doctors on how to prescribe the drugs. (Reporting by Jan Wolfe; Editing by Howard Goller)
Our Standards: The Thomson Reuters Trust Principles.